Bronchial cancer is cancer that begins in the tissue lining the airways (bronchi) of the lungs. It accounts for the vast majority of what people commonly call lung cancer, and it includes both small cell and non-small cell types. Because symptoms rarely appear until the disease has advanced, understanding the risk factors, warning signs, and screening options can make a meaningful difference in outcomes.
Where Bronchial Cancer Starts
Your lungs contain a branching network of airways called bronchi, which carry air from your windpipe down into smaller and smaller passages. These airways are lined with specialized cells, and bronchial cancer develops when those cells begin growing out of control. The specific location and cell type involved determine which form of cancer develops.
In squamous cell carcinoma, a common subtype, the cancer appears to originate in the flat basal cells that line the upper airways. In adenocarcinoma, another common subtype, the cancer tends to arise from cells located deeper in the lungs, near the junctions where airways end and the tiny air sacs (alveoli) begin. Genetic changes drive this process. One well-studied example involves a gene called Sox2, which normally helps airway cells grow and mature. When that gene gets amplified through a chromosomal error, it can push cells toward uncontrolled growth.
Non-Small Cell vs. Small Cell
Bronchial cancer falls into two broad categories, and the distinction matters because they behave very differently.
Non-small cell lung cancer (NSCLC) makes up roughly 80 to 85 percent of all lung cancers. It includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC generally grows more slowly than its counterpart and is more likely to be caught at a stage where surgery is still an option. Five-year survival for localized NSCLC is 67 percent, dropping to 40 percent when it has spread to nearby lymph nodes and 12 percent when it has reached distant organs.
Small cell lung cancer (SCLC) accounts for the remaining 15 to 20 percent. It grows and spreads much faster, and it is strongly linked to heavy smoking. The survival numbers reflect that aggressiveness: 34 percent for localized disease, 20 percent for regional spread, and 4 percent for distant metastasis. SCLC is more likely to have already spread by the time it’s found.
Risk Factors
Smoking is the leading cause of bronchial cancer by a wide margin, but it is not the only one. Several environmental and occupational exposures raise risk independently.
- Radon. This naturally occurring gas seeps from rocks and soil into homes, particularly through basements and lower floors. It is the second leading cause of lung cancer in the United States and can cause the disease even in people who have never smoked. Radon can also be present in well water.
- Workplace exposures. Asbestos, arsenic, diesel exhaust, certain forms of silica, and chromium compounds all increase risk. People who work in construction, mining, manufacturing, or transportation may face higher exposure.
- Secondhand smoke and air pollution. Long-term exposure to either raises your risk, though less dramatically than direct smoking.
Arsenic in drinking water, particularly from private wells, is another recognized risk factor that many people are unaware of.
Symptoms and When They Appear
Bronchial cancer typically causes no symptoms in its early stages. By the time noticeable signs develop, the disease is often advanced. This is one of the main reasons survival rates are lower than for cancers that produce early warning signs.
When symptoms do appear, they commonly include a persistent new cough, chest pain, shortness of breath, wheezing, hoarseness, and coughing up blood (even a small amount). These symptoms overlap with many less serious conditions, which can delay diagnosis. If the cancer has spread beyond the lungs, you may also notice bone pain, headaches, or unexplained weight loss.
How Bronchial Cancer Is Diagnosed
A tissue biopsy remains the definitive way to confirm bronchial cancer. The most common route to that biopsy is bronchoscopy, a procedure where a thin, flexible tube with a camera is guided through your mouth or nose into the airways. For tumors located in the central airways, bronchoscopy detects cancer about 88 percent of the time. For tumors deeper in the lungs, detection rates are more variable, ranging from 36 to 88 percent depending on the technique used.
Standard white-light bronchoscopy can miss very early lesions. Studies have shown it detects only about 29 percent of carcinoma in situ (the earliest stage, where abnormal cells haven’t yet invaded deeper tissue) and 69 percent of microinvasive tumors. Newer techniques help close that gap. Autofluorescence bronchoscopy shines blue or violet light on airway tissue; healthy tissue glows green, while abnormal areas appear red or magenta due to differences in their internal structure. Optical coherence tomography creates cross-sectional images of the airway wall, revealing where the normal layered structure has been disrupted by a tumor.
Staging and What It Means
Once bronchial cancer is confirmed, staging determines how far it has spread. Doctors use the TNM system, which evaluates three things: the size of the primary tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has metastasized to distant organs (M). Each element is assigned a number, with higher numbers indicating more extensive disease.
For practical purposes, staging is often simplified into three categories. Localized means the cancer is confined to the lung where it started. Regional means it has spread to nearby lymph nodes or structures. Distant means it has reached other parts of the body, such as the bones, brain, or liver. Your stage at diagnosis is the single most important factor in determining treatment options and prognosis.
Treatment Approaches
Treatment for bronchial cancer depends on the type (small cell vs. non-small cell), the stage, and your overall health. For early-stage NSCLC, surgery to remove the tumor or affected portion of the lung is the primary approach. Radiation therapy may be used alongside surgery or as an alternative for people who can’t undergo an operation. Chemotherapy is standard for more advanced disease and is the backbone of treatment for small cell lung cancer at any stage.
Targeted Therapy and Genetic Testing
One of the most significant advances in bronchial cancer treatment is the use of targeted therapies, which work against specific genetic mutations found in some tumors. About 15 to 20 percent of non-small cell lung cancers carry mutations in a gene called EGFR. Patients with these mutations respond significantly better to drugs that block the EGFR protein than to traditional chemotherapy. Another important target is the ALK gene rearrangement. In clinical trials, patients with ALK-positive tumors who received a targeted drug saw response rates of 65 percent, compared to 20 percent with standard chemotherapy, and their disease was held in check for more than twice as long.
Other treatable genetic changes include BRAF mutations, ROS1 rearrangements, and HER2 alterations. Because of this, molecular testing of tumor tissue has become a routine part of diagnosis for non-small cell lung cancer. The results determine whether you’re a candidate for these more precise treatments, which generally cause fewer side effects than conventional chemotherapy.
Screening for Early Detection
Because bronchial cancer so often escapes notice until it’s advanced, screening can catch it when survival odds are highest. The U.S. Preventive Services Task Force recommends annual low-dose CT scans for adults aged 50 to 80 who have a smoking history of at least 20 pack-years and either currently smoke or quit within the past 15 years. A pack-year equals smoking one pack (20 cigarettes) per day for one year, so someone who smoked two packs a day for 10 years would have a 20 pack-year history.
Screening should stop once you’ve been smoke-free for 15 years or if a health condition limits your life expectancy or your ability to undergo treatment. The scan itself is quick and painless, using a much lower dose of radiation than a standard CT. For people who qualify, it represents the best available tool for finding bronchial cancer at its most treatable stage.